Skip to content

Gellan Contact Study

Prospective, Randomized Control Trial to Evaluate the Dermatological Reaction of Healthy Volunteers to Gellan Sheet and Fluid Gel Dressings (Gellan Contact Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04044014
Acronym
GCS
Enrollment
33
Registered
2019-08-02
Start date
2016-10-10
Completion date
2017-08-01
Last updated
2019-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Burn, Thermal Injury

Keywords

Gellan, thermal injury, healthy volunteers, skin

Brief summary

The primary objective of this study will be to establish the safety of the two different Gellan formulations (sheet and fluid gel) following its application to the epidermis of healthy volunteers. This will be compared to a control dressing-- Mepitel One (Polyurethane net with soft Silicone).

Detailed description

This contact study is part of the Wellcome trust Anti-scarring Dressing project to develop a carrier dressing that will be used to deliver therapeutic agents to the skin. A polysaccharide, Gellan, has been chosen as the main component of this dressing (the biomembrane)and it can be produced in either a sheet or fluid gel forms. Gellan is a widely used material in both the food and medical industry e.g. as a lubricant in eye-drops (e.g. Timoptol XE, Merck Sharp & Dohme, USA). As part of the development of the dressing, the epidermal (skin) response to Gellan needs to be evaluated to check its safety. The main objective of this study is to establish the safety of the two different Gellan formulations (2% Gellan sheet and 2% Gellan fluid gel) following application to the epidermis (skin).

Interventions

DEVICEGellan sheet

Gellan sheet.

DEVICEGellan fluid gel

Gellan fluid gel.

Control dressing-- Mepitel One.

Sponsors

Wellcome Trust
CollaboratorOTHER
University Hospital Birmingham
CollaboratorOTHER
University of Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Masking description

Two assessors will be evaluating the skin for erythema, dryness and oedema. They will be blinded to which arm has received the treatment and control.

Intervention model description

Participants will be randomised to receive the treatment dressing (either the Gellan sheet or Gellan fluid gel) on one arm (Left or Right), and the control dressing (Mepitel One) on the other arm. The first phase will be for 1 hour and the 2nd phase will be for 3 days.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male or female subjects aged ≥ 18 years old * Subjects who can provide informed consent

Exclusion criteria

* Subject with existing skin conditions/diseases which may interfere with the aim(s) of the study. Examples include pathological fibrosis e.g. scleroderma; pathological thinning e.g. epidermolysis bullosa and collagen disorders e.g. Marfan's syndrome * Chronic steroid use, history of skin malignancy or chronic papulo-squamous disease (e.g. eczema, pemphigus) and history of Steven Johnson or TENS disease * Blemishes, marks (e.g. tattoos, scars or burns,) on the test site(s) which may interfere with assessment on the test site * Use of medication which may affect may affect skin response * Known allergy to the materials used in the study * Known allergy to adhesive plasters or tapes * Fitzpatrick skin type VI (due to the difficulty of identifying erythema) * Irritated skin on the test site * Known pregnancy (confirmed by urine pregnancy test) or lactating * Inability to commit to attending all sessions. * Participation in another study which may affect the results of this contact study. * Any other reason that clinician considers will interfere with the objectives of the study

Design outcomes

Primary

MeasureTime frameDescription
Skin reaction3 days (72 hours+/-3 hours)Skin will be evaluated for erythema, dryness and oedema by two observers using a visually based scale (Visual skin assessment scale; this is a novel scale devised by the research team). The scale is as follows: 1. Erythema: 0-4 (Higher values are worse) 2. Dryness: 0-3 (Higher values are worse) 3. Oedema: 0-1 (Higher values are worse) Each subscale is evaluated individually and not combined.

Secondary

MeasureTime frameDescription
Participant satisfaction with dressingAt end of study (after 3 days)Participant satisfaction in terms of pain, itch, comfort and ease of removal (evaluated using a questionnaire). Name of questionnaire: Participant evaluation questionnaire Questions: 1. Was the dressing comfortable? (Yes/No) 2. Was there any itch? (Yes/No) 3. Was there any pain? (Yes/No) 4. Was the dressing comfortable to remove? (Yes/No)
Clinician satisfaction with dressingAt end of study (after 3 days)Clinician satisfaction in terms of ease of application, handling, removal, durability, conformity (evaluated using a questionnaire). Name of questionnaire: Clinician evaluation questionnaire Questions: 1. Is the dressing still moist? (Yes/No) 2. Is the dressing still intact? (Yes/No) 3. Has any fragmentation occurred? (Yes/No) 4. Has any tearing occurred? (Yes/No)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026